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Summary
Background: Cardioembolic stroke accounts for about one third of all strokes. Microembolic
signals (MES) are frequently found in patients with acute stroke. The role of MES in cardioembolic
stroke is less well investigated.
Methods: Medline based literature review of clinical trials linking MES and stroke with cardiac
sources of various risks.
Results: MES are a rare ﬁnding in patients with cardioembolic stroke as well as in sources
of potential cardiac embolism (e.g. myocardial infarction, atrial ﬁbrillation, left ventricular
thrombus). The low number of patients with MES and the low number of MES during the inves-
tigation times leads to a limited statistical power of positive and negative ﬁndings. MES in
patients with artiﬁcial heart valves and the DeBakey left ventricular assist device (LVAD) are
predominantly gaseous and do not correlate with stroke risk. In patients with the Novacor LVAD,
MES strongly correlate with stroke risk.
Conclusion: Currently, the role of MES in cardioembolic stroke is only limited due to both, the
low prevalence of MES and the number of MES per investigation. Larger studies would be needed
to strengthen this role.
© 2012 Published by Elsevier GmbH.
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ardioembolic stroke accounts for about one third of all
trokes. In some registries, percentages even reach 40%. The
iagnosis of cardioembolic stroke requires that alternative
troke etiologies have been ruled out comprehensively. Diag-
osis of cardiac embolism thus usually requires the presence
f a structural abnormality of the heart or the diagnosis of
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Open access under CC BY-NC-hythm disturbances with high embolic risk such as atrial
brillation (AF) [1].
According to general consensus, cardiac lesions can be
ivided into ‘‘high risk’’ and ‘‘low or uncertain risk’’ of sub-
equent embolism [2]. The differentiation is of considerable
mportance, as the therapeutic regimen to prevent future
mbolism varies between different embolic risks. Table 1
ives an overview of ‘‘high’’ and ‘‘low’’ risk lesions.
Even without proving a cardiac source, some features of
n acute stroke give clues to a cardiac source of stroke.
or example, patients with cardioembolic stroke frequently
ave clinically more severe stroke than others, frequently
ecreased level of consciousness, and severe cortical symp-
oms such as neglect or aphasia [2]. On cerebral imaging
specially multiple lesions in different arterial territories
ND license.
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Table 1 High and low risk lesions for cardiac embolism [2].
High risk Low risk
Atrial Atrial
Atrial ﬁbrillation Patent foramen ovale
Atrial ﬂutter Atrial aneurysm
Sick sinus syndrome Spontaneous echo
contrast
Left atrial thrombus
Left atrial myxoma
Ventricular Ventricular
Left ventricular
thrombus
Dyskinetic wall
segments
Left ventricular myxoma Hypertrophic
cardiomyopathy
Recent myocardial
infarction
Congestive heart failure
Dilated cardiomyopathy
Valvular Valvular
Mitral stenosis Lambl’s excrescences
Prosthetic valves Fibroelastoma
Table 2 Prevalence of MES in various stroke etiologies.
Author, year Large artery
embolism
n/N, %
Cardioembolic
stroke n/N %
Small vessel
disease n/N
%
Idicula,
2010 [4]
4/13, 30% 4/7, 36% 0/2, 0%
Poppert,
2006 [5]
20/103, 20% 5/143, 3.5% 0/147, 0%
Serena,
2000 [6]
8/39, 20% 6/35, 17% 0/64, 0%
Kaposzta,
1999 [7]
10/20, 50% 1/22, 4% 0/20, 0%
Daffertshofer, 18/105, 4/65, 6.2% 3/67, 4.5%
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endocarditis
Mitral-valve prolapse
strongly favours a cardiac source of embolism. Furthermore,
microembolic signals (MES) detected in both middle cere-
bral arteries make a proximal source of embolism, mainly
the heart, very likely [2].
Microembolic signals (MES) are frequently found in
patients with acute stroke and especially in those with
symptomatic carotid stenosis [3]. The role of MES in car-
dioembolic stroke is less well investigated. The following
overview will highlight the current role of MES detection
in the diagnosis and therapy of various sources of cardiac
embolism.
Methods
Medline listed studies were identiﬁed by the following
search terms: ‘‘MES’’ OR ‘‘ES’’ OR ‘‘HITS’’ AND ‘‘Cardia*’’
OR ‘‘heart’’ OR ‘‘atri*’’ OR ‘‘ventri*’’. Studies were
selected upon relevance to the subtitles of the following
overview. If appropriate, data from different studies were
grouped in tables and commented in context.
Prevalence of MES in patients with cardioembolic
stroke
There are a number of studies investigating the prevalence
of MES in unselected stroke cohorts. An overview on the
studies comparing the prevalence of MES in detailed stroke
etiologies according to TOAST criteria is given in Table 2.
In a recent study, Idicula found quite a high prevalence
of MES in patients with cardiac embolism that even topped
the prevalence found in patients with symptomatic carotid
stenosis [4]. However, in this study, only 40 patients had
been included in total and MES were found in four of eleven
patients with cardiac embolism. In the larger studies the
S
t
s1996 [8] 17.1%
Sum 60/280, 21% 20/272, 5% 3/300, 1%
revalence of MES was generally low. The lowest percentage
as found in the largest study of Poppert and colleagues,
nding MES in only ﬁve of 143 (3.5%) patients with cardiac
mbolism [5]. The overall prevalence of MES in patients with
ardio-embolic stroke is about 5%. No study found MES to be
redictive of recurrent cardioembolic stroke, which could
lso be the effect of the low case numbers with MES and the
estricted observation times.
Ferro commented in his paper that cardioembolic stroke
hould be assumed in case MES are found bilaterally [2].
owever although this assumption is quite plausible, its clin-
cal relevance is very low. First, as mentioned above, only
minority of patients with cardioembolic stroke will have
ES at all. Second, the number of MES per investigation is
ery low (about 1 or 2 MES per hour). Finding larger numbers
f MES is rare. However, bilateralism cannot be assumed in
ase of only one MES per session and even with two signals
uring the session there is still a 50% chance that these two
ignals occur on the same side of the brain.
Furthermore, bilateral MES can also be found in cases
ith artery to artery embolism. Poppert et al. found in his
tudy bilateral MES in 3 of 20 patients with this stroke etiol-
gy [5]. In one patient, contralateral carotid occlusion may
ave accounted for this ﬁnding, but no obvious reason was
epicted in two cases. In summary, MES are an infrequent
nding in cardioembolic stroke, MES detection does thus not
ontribute to the work-up of unselected stroke patients to
etermine stroke etiology.
ES in cardiac disease with a risk of stroke
his paragraph will look at cardiac embolism from the other
ide of the medal. What does MES detection contribute
o the patients’ work-up in case there are known cardiac
esions and the investigator wants to address the risk of
uture stroke.
ES after myocardial infarctiontroke is a possible complication of acute myocardial infarc-
ion and affects 2—3% of patients with acute coronary
yndromes (ACS) [9]. The risk to suffer stroke within the
216
Table 3 Prevalence of MES in various sources of cardiac
embolism [12].
Cardiac pathology n Prevalence of MES
Infective endocarditis 7 43%
Left ventricular aneurysm 38 34%
Intracardiac thrombus 23 26%
Dilated cardiomyopathy 39 26%
Non-valvular atrial ﬁbrillation 24 21%
Valvular disease 80 15%
Prosthetic heart valves 89 55%
Overall 23% (without
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0 days after myocardial infarction is about 10 times higher
han before and thereafter. It is therefore reasonable to use
ES detection as a predictor of future stroke in this setting.
Nadareishvili et al. found MES in 17 of 100 patients within
2 h from onset of an acute coronary syndrome [10]. MES
ere more frequently found in patients with LV thrombus,
kinetic left ventricle and decreased ejection fraction on
chocardiography. They also found that during the follow-
ng days 3 patients suffered stroke, all of which had MES at
aseline [10].
Unfortunately, these results could not be reproduced in
recent study from Spain, in which 209 patients with ACS
ad been investigated with a very similar protocol [11]. The
uthors found MES in only 7 patients (prevalence of 3.4%)
nd patients were followed for 14months. In the follow-
p period, only 3 patients had a subsequent stroke, none
f them had MES at baseline. Apart from stroke, no other
ascular event could be predicted by the presence of MES.
Overall, the data are thus inconclusive, again in part due
o the low prevalence of MES in this cohort and the low
verall case number in the studies. From a practical point
f view, MES detection does not seem to be very helpful in
redicting stroke after ACS.
ES in other cardiac sources of embolism
eorgiadis et al. reported in his milestone paper on this
ubject the prevalence of MES in 300 patients with vari-
us cardiac sources of embolism [12]. The detailed numbers
re given in Table 3. The highest prevalence was found for
atients with infective endocarditis, the lowest for chronic
alvular disease. No associations could be found for MES and
atients’ age or sex or actual medication. Only ‘‘high risk
esions’’ according to Table 1 were investigated. Although
he study was quite large, no data on patient outcome and
he risk of future stroke for patients with and without MES
re given. Thus, for most of the sources prospective studies
ould be needed to determine the role of MES detection to
redict future cardioembolic stroke.ES in atrial ﬁbrillation
trial ﬁbrillation is the single most frequent cause of car-
ioembolic stroke. No wonder MES detection has been used
o
h
(
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n a number of studies in this entity. Studies have tried to
etermine the prevalence of MES, the risk of patients with
ES to suffer subsequent stroke and to correlate the pres-
nce of MES with anticoagulation therapy.
In the paper of Georgiadis et al., 5 of 24 patients (21%)
ith atrial ﬁbrillation (AF) had MES [12]. Nabavi et al. found
ES in 11 of 26 patients (42%) with valvular AF compared
ith 3 of 21 patients (21%) with non-valvular AF [13]. MES
ere also more frequently found in patients with a history
f thromboembolism. Cullinane et al. found MES in 13 of
6 patients with non-valvular AF (15%) [14]. There was no
ifference in the prevalence between symptomatic (16%)
nd asymptomatic (13%) patients. Furthermore, there was
o correlation between MES and the use of aspirin or left
trial thrombus. There was also no correlation between
ES and echocardiographic risk markers (such as left atrial
nlargement). One study investigated, whether MES were
ore frequent in 37 patients with stroke due to AF compared
ith 10 patients with AF but without stroke and 92 controls
15]. MES were detected in 11 (29%) of the symptomatic
atients and only in one without a history of stroke. The
ES count was quite high in this study with ∼15 events per
our which sheds some doubt on the credibility of the data.
ver a follow-up period of 18months one patient with MES
t baseline had a recurrent stroke; however this occurred
year from study inclusion.
Overall, studies were too small to address the question
f stroke risk and studies are too heterogeneous to perform
meta-analysis of studies performed. Until larger studies
eport otherwise, there seems to be no added value of MES
etection to address clinical questions in patients with AF.
ES and left ventricular assist devices
ES detection is a well-established method to monitor car-
iac or vascular procedures. Currently, a well-established
rocedure is the implantation of cardiac left ventricular
ssist devices (LVAD) that allow ‘‘bridging’’ of patients
ith very severe left ventricular cardiac failure to heart
ransplantation or until the heart has recovered from a
emporary disease. These patients are constantly endan-
ered by the occurrence of systemic and frequently cerebral
mbolism although antiplatelet and anticoagulation strate-
ies are both used to decrease this risk. These patients are
ell characterised and an attractive group of patients to
est whether silent microembolism is associated with clini-
al events. In one study, 20 patients with the Novacor N100
VAD were investigated [16]. MES detections were performed
nce weekly for 30min, and thromboembolic events were
ecorded. 44 events occurred in 3876 LVAD days resulting
n an incidence of 1.1% events per day (400%/year). The
verall MES prevalence was 35.3% with a median MES num-
er of 2.3/h. There was a strong correlation between MES
ctivity and incidence of thromboembolism and times with
vents were predicted by MES activity with a moderate
ositive predictive value (0.37—0.7) and a high negative
redictive value (0.82—1.0). Concerning therapy, patients
n both medications, oral anticoagulants and antiplatelets,
ad less events (0.7% vs. 2.8%) and a lower MES prevalence
18.3% vs. 65.4%) than patients on anticoagulation alone.
herefore, MES detection seems very useful in patients with
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the Novacor device as it correlates with therapy and clini-
cal events. In another study patients with the DeBakey were
investigated [17]. 23 patients were monitored twice weekly
with and without oxygen inhalation. Therapy and documen-
tation of clinical events was identical to the ﬁrst study.
In these patients the embolic risk of 0.24%/per day was
80% less than for patients with the Novacor LVAD, although
the prevalence of MES (35.1%) was the same as in Novacor
patients and the number of MES was much higher (mean
81± 443/h) than in the Novacor device. The authors found
no correlation between MES activity and incidence of throm-
boembolism or hemostatic treatment for patients with the
DeBakey device. The authors also found that the number of
MES with the DeBakey device decreased signiﬁcantly after
oxygen inhalation suggesting a gaseous nature of most of the
MES in patients with the DeBakey device. Gaseous MES have
been shown to not correlate with stroke risk, something that
has been observed with artiﬁcial heart valves in the past.
Sliwka and Georgiadis retrospectively evaluated 369
patients with various types of artiﬁcial heart valves
>3months concerning the risk of stroke and the presence
and number of MES [18]. They found signiﬁcant differences
in MES prevalence and counts depending on valve type.
Although the prevalence of MES ranged from 9% (biological
valves) to 92% (Björk Shiley) and the average MES numbers
from 0 to 133 per hour there was no association between MES
counts and INR, age, cardiac rhythm, and implant duration.
There was also no predictive value of MES for a history of
neurological symptoms which were prevalent in 42 patients.
In summary, MES detection seems useful in patients with
Novacor LVAD to guide therapy and to predict clinical events.
However this does not hold true for patients with the
DeBakey LVAD and not for patients with artiﬁcial heart valves
as most MES in these patients are from gaseous nature.
Conclusion
MES are an infrequent ﬁnding in most cardiac sources of
embolism and due to the low case numbers in most stud-
ies and the low absolute number of MES any conclusion
is premature. Much larger studies would be needed with
homogeneous study populations to address most questions
covered in this review, especially to monitor therapeutic
effects or to predict future strokes. From a pragmatic point
of view, there is currently no established role of MES detec-
tion in cardiac embolism.
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